Instrument Inactif

Autres langues TxCell CBOE

Actions

0QTN

FR0010127662

Recherche biotechnologique et médicale

Cours en clôture CBOE
- ^EUR	-

03/12/18	TxCell : acquisition par Sangamo finalisée
27/11/18	TxCell : retrait obligatoire ce jeudi

Autres langues

01/10/18	TxCell : Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares
23/07/18	TxCell : Sangamo Therapeutics to Acquire TxCell
09/07/18	TxCell : exercises in-license option to the University of British Columbia’s intellectual property rights of the HLA-A2 CAR-Treg program
21/06/18	TxCell : First in vivo proof-of-concept data with CD8+ CAR-Treg presented at FOCIS 2018
28/05/18	TxCell : to present its latest manufacturing process achievements at the 3rd Annual Bioprocessing of Advanced Cellular Therapies Congress
06/04/17	TxCell : 2016 financial results
06/04/17	TxCell : to hold conference call on Friday, March 10, 2017 following the publication of its 2016 financial results
26/09/16	TXCELL : September 2016 - TxCell to publish results for the first half of 2016 and to provide strategy update on Tuesday, September 27, 2016
05/09/16	TxCell : appoints Biogen’s Dr. Olivier Danos, pioneer in gene therapy for neurological disorders, to its Scientific Advisory Board
24/08/16	TxCell: financial information for the 2nd quarter of 2016
27/07/16	TxCell : to participate in leading scientific conferences in Q3 2016
11/07/16	TxCell : exercises option from Weizmann Institute of Science following effective grant of broad CAR-Treg patent in Europe
21/06/16	TxCell : implements a new financing contract of up to €20 million in nominal value through convertible notes with warrants (OCABSA)
14/06/16	TxCell : and the Lübeck Institute of Experimental Dermatology launch collaboration to develop CAR-Tregs in bullous pemphigoid
01/06/16	TxCell : presents a series of new scientific data at the ISCT 2016 Annual Meeting
25/04/16	TxCell: financial information for the 1st quarter of 2016
20/04/16	TxCell : to participate in leading scientific conferences in Q2 2016
31/03/16	TxCell : appoints PCT as its US manufacturing partner
15/03/16	TxCell : 2015 results and update on strategy and outlook
10/03/16	TXCELL : Key TxCell patent to be granted in Japan for its lead product Ovasave®
25/02/16	TxCell : to present its latest cellular immunotherapy developments at leading investor conferences in Q1 2016
25/01/16	TxCell : makes available the prospectus for implementation of a two-year, no-minimum-draw Standby Equity Facility (SEF®)
08/01/16	TxCell : announces its financial calendar for 2016
08/01/16	TxCell : Full-year report on liquidity contract with Oddo Corporate Finance
08/01/16	TxCell : monthly information regarding the total number of voting rights and the total number of shares